US › Healthcare

Ardelyx Inc (ARDX)

US · Healthcare · Biotechnology

$5.01+0.60%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$94.5M
Revenue YoY
+27.5%
Net profit
$-37.6M
Profit YoY
+8.6%
EPS
$-0.15
EPS estimate
$-0.14
Net margin
-39.8%

EPS came in at -0.15 against a street estimate of -0.14 — a miss of 7.1%.

Key statistics

Market cap
$1.22B
Forward P/E
40.7
P/B
8.24
Book value
$0.60
EPS (TTM)
$-0.24
52-week high
$8.40
52-week low
$4.71
50-day MA
$5.54
200-day MA
$6.03
Beta
0.60

Analyst view

Analysts rate Ardelyx Inc a strong buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $16.30.

Shareholding

Insiders
3.26%
Institutions
70.83%

Largest institutional holders

FundStake
BlackRock Inc8.57%
Millennium Management LLC7.22%
State Street Corp5.51%
Vanguard Capital Management, LLC4.20%
HHG PLC3.39%
Delaware Management Holdings Inc3.31%
Vanguard Portfolio Management, LLC2.70%
Geode Capital Management, LLC2.43%

Recent filings & reports

DocumentDate
Current report · Q2 20262026-07-02
Board / officer change · Q2 20262026-06-17
Quarterly report · Q1 20262026-04-30
Results announced · Q2 20262026-04-30
Proxy statement · Q2 20262026-04-29
Annual report FY20252026-02-19
Results announced · Q1 20262026-02-19
Quarterly report · Q3 20252025-10-30

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ardelyx Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.